Galantamine
In brief
- In our pharmacy, you can buy galantamine without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging is available.
- Galantamine is used to treat cognitive decline in mild–moderate Alzheimer’s disease; it is a reversible acetylcholinesterase inhibitor and also a positive allosteric modulator of nicotinic acetylcholine receptors, increasing synaptic acetylcholine.
- The usual dose is to start at 4 mg twice daily (immediate‑release) or 8 mg once daily (extended‑release), increasing every 4 weeks as tolerated to a maintenance target of 16–24 mg per day (divided doses); lower maxima (eg 16 mg/day) are recommended for moderate hepatic or renal impairment and it is not recommended in severe impairment.
- Administered orally as immediate‑release tablets (4 mg, 8 mg, 12 mg), prolonged/extended‑release capsules (8 mg, 16 mg, 24 mg) or an oral solution (4 mg/mL).
- Plasma levels rise within about 1–2 hours after an immediate‑release dose (extended‑release formulations peak later); clinically noticeable changes in cognition may take several weeks, typically observed after 4–6 weeks of treatment.
- Immediate‑release doses generally cover approximately 8–12 hours per dose, while extended‑release formulations provide once‑daily coverage (up to 24 hours); the elimination half‑life is around 7 hours.
- Avoid alcohol while taking galantamine as it can increase drowsiness, dizziness and gastrointestinal side effects and may worsen cognitive impairment.
- The most common side effect is nausea, often accompanied by vomiting, diarrhoea, decreased appetite and abdominal discomfort; other common effects include dizziness, headache, insomnia and fatigue.
- Would you like to try galantamine without a prescription?
Legal status and availability in the UK
Galantamine is a prescription-only medicine (POM) in the UK.
In our online pharmacy, galantamine is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Basic galantamine information
- INN (international nonproprietary name): Galantamine
- Brand names available in the United Kingdom: Reminyl (Janssen-Cilag); generic galantamine
- ATC code: N06DA04 — anti-dementia drugs (anticholinesterase inhibitor)
- Forms and dosages: immediate‑release tablets 4mg/8mg/12mg; prolonged‑release capsules 8mg/16mg/24mg; oral solution 4mg/mL
- Manufacturers in the United Kingdom: Janssen‑Cilag (Reminyl) and generic manufacturers
- Registration status in the United Kingdom: authorised by the MHRA; prescription-only medicine (POM)
- OTC / Rx classification: Prescription-only medicine (POM)
What galantamine is — pharmacological overview
Mechanism and origin
What does galantamine actually do in the brain?
Galantamine is an acetylcholinesterase inhibitor that raises synaptic acetylcholine by reversible inhibition of acetylcholinesterase.
It also acts as an allosteric potentiating ligand at nicotinic acetylcholine receptors, which may enhance cholinergic transmission further.
Those combined mechanisms underpin modest improvements in cognition and activities of daily living for some patients with mild‑to‑moderate Alzheimer’s disease.
Pharmacologically it originates from alkaloids in the Amaryllidaceae family, although most pharmaceutical galantamine is now produced synthetically.
Classification
ATC code N06DA04 classifies galantamine among centrally acting anticholinesterases used for dementia syndromes. In the UK it is marketed as Reminyl and as generic galantamine, and treatment should be started and monitored by an appropriate clinician.
Effect sizes are modest and response is variable; counselling should set realistic expectations about potential benefits and tolerability.
Formulations, strengths and packaging
Available presentations
Which presentations are available when choosing a product?
Immediate‑release tablets are available in 4mg, 8mg and 12mg strengths.
Extended or prolonged‑release capsules are supplied in 8mg, 16mg and 24mg strengths.
An oral solution is supplied at 4mg/mL.
Choosing immediate vs extended‑release
Which form suits the patient best?
Extended‑release formulations allow once‑daily dosing which can improve adherence and reduce peak‑related nausea.
Immediate‑release tablets permit divided dosing and more flexible titration when clinicians want to adjust dose more rapidly.
Packaging options vary between blister packs and bottles, which affects dispensing preferences and patient ease‑of‑use.
| Formulation | Strengths | Dosing frequency | Patient suitability |
|---|---|---|---|
| Immediate‑release tablets | 4mg, 8mg, 12mg | Twice daily (divided) | Allows split dosing and slow titration; useful for early tolerance checks |
| Prolonged‑release capsules | 8mg, 16mg, 24mg | Once daily | Useful for adherence; may reduce peak GI effects |
| Oral solution | 4mg/mL | Varies by prescribed volume | Suitable when swallowing is a problem or for precise dosing |
- Manufacturers to note: Janssen‑Cilag (originator Reminyl), Gedeon Richter, Zentiva, Sandoz, Teva, Hexal, Accord, Mylan.
Standard dosing, titration and administration
Typical titration schedules
How should dosing start and increase safely?
For mild–moderate Alzheimer’s, start immediate‑release 4mg twice daily or ER 8mg once daily.
Increase the dose every four weeks as tolerated toward a target daily dose of 16–24mg depending on clinical response and formulation.
Immediate‑release total daily dose is given in divided doses; extended‑release is given once daily.
For moderate renal or hepatic impairment a maximum of 16mg/day is recommended with slower titration; severe impairment is not recommended.
Practical administration tips
How to counsel carers and patients on taking the medicine?
Take galantamine with food to reduce nausea.
Swallow extended‑release capsules whole and do not crush them.
Use a calibrated device to measure oral solution and match prescribed milligrams to millilitres.
If a dose is missed, take it when remembered unless the next dose is imminent; do not double the next dose.
| Stage | Example schedule |
|---|---|
| Start IR | 4mg twice daily |
| Start ER | 8mg once daily |
| Titration | Increase every 4 weeks as tolerated to 16–24mg/day |
Administration do’s and don’ts
- Do take with food to reduce GI upset.
- Do not crush or chew ER capsules.
- Do monitor weight and fluid intake during early weeks.
- Don’t double doses if one is missed close to the next scheduled dose.
Contraindications and key cautions
Absolute contraindications
Which patients must not receive galantamine?
Absolute contraindications include a history of hypersensitivity to galantamine or any excipient.
Severe hepatic impairment and severe renal impairment are also exclusions.
Active or recent gastric or duodenal ulcers and severe, uncompensated cardiac conduction disorders are also contraindications.
Important relative cautions
Which situations require caution or additional checks?
Relative cautions include asthma or COPD because of potential bronchospasm and patients with a history of seizures due to increased seizure risk.
Urinary outflow obstruction, sick sinus syndrome and conduction abnormalities warrant ECG review and liaison with the prescriber.
Concurrent medicines that slow heart rate, such as beta‑blockers and digoxin, increase bradycardia risk.
Side‑effect profile and mitigation strategies
Common adverse effects and counselling
What side effects should patients and carers expect?
Common adverse effects are mostly cholinergic and include nausea, vomiting, diarrhoea, anorexia and weight loss.
CNS effects such as dizziness, headache and insomnia may occur.
Cardiovascular effects include bradycardia and rare syncope, so monitor pulse and falls risk particularly in older, frail patients.
Mitigation strategies include starting at a low dose, titrating slowly, taking the medicine with food and checking hydration and nutrition.
Managing serious reactions
Which reactions need urgent action?
Serious reactions include severe bradycardia, syncope, seizure activity and significant gastrointestinal bleeding.
Advise immediate medical review and drug review if any of those occur.
Report suspected adverse drug reactions via the Yellow Card scheme for UK pharmacovigilance.
- Red flags for carers: Persistent vomiting, fainting or near‑fainting, sudden worsening confusion, new seizures or very slow heartbeat.
Drug interactions and monitoring in practice
CYP interactions and additive effects
Which medicines change galantamine levels or effects?
Galantamine is metabolised by CYP2D6 and CYP3A4.
Strong inhibitors such as ketoconazole or fluvoxamine can raise galantamine levels and warrant caution or dose reduction.
Strong inducers such as carbamazepine may reduce galantamine plasma concentrations and clinical effect.
Concurrent cholinergic agents or other acetylcholinesterase inhibitors increase cholinergic effects, and succinylcholine use is a potential interaction of concern.
Co‑prescribing with heart rate‑lowering drugs (beta‑blockers, digoxin) increases the risk of symptomatic bradycardia.
Monitoring parameters
Baseline pulse and blood pressure are recommended, with ECG if there is a history of conduction disease or syncope.
Monitor renal and liver function at baseline and periodically, and check weight and nutritional status.
For older patients with polypharmacy, review overall anticholinergic burden and fall risk during medication reviews.
| Concomitant drug | Interaction | Action |
|---|---|---|
| Ketoconazole / Fluvoxamine | Increase galantamine levels via CYP inhibition | Consider dose reduction or close monitoring |
| Carbamazepine | Reduced galantamine levels via enzyme induction | Monitor for reduced efficacy |
| Beta‑blockers / Digoxin | Increased risk of bradycardia | Check pulse; consider ECG and prescriber review |
Special populations
Older adults and practical dosing
How should frail older adults be managed differently?
Older adults are the primary users, and frailty increases the risk of side‑effects such as falls and weight loss.
Start at the lowest recommended dose and titrate slowly while prioritising functional outcomes over modest changes in cognitive scores.
Monitor for dehydration, weight loss and worsening gait or balance during early treatment.
Renal/hepatic adjustment
What to do when renal or hepatic function is impaired?
For moderate renal or hepatic impairment a maximum of 16mg/day is advised with slower titration.
Severe renal or hepatic impairment is not recommended for treatment with galantamine.
Switching between galantamine products and generic substitution
Practical switching protocol
What is the safe way to switch formulations or brands?
Ensure the equivalent total daily dose when converting between immediate‑release and extended‑release formulations.
Monitor closely for tolerability during the first one to two weeks after a switch.
Tell the prescriber if any unusual adverse effects emerge.
Counselling after substitution
What should carers be told when their relative receives a different brand?
Warn about a transient increase in GI effects after switching and remind carers to monitor heart rate and dizziness.
Advise keeping a simple symptom diary for the first fortnight and to contact the pharmacist or prescriber for persistent problems.
Expected benefit and outcomes
Efficacy snapshot
How effective is galantamine in practice?
Clinical trials and regulatory approvals note modest cognitive and functional benefits in mild‑to‑moderate Alzheimer’s disease.
Effect sizes are generally small and vary between individuals, with some stabilisation or slowed decline observed in responders.
Benefits are usually assessed over months and decisions on continuation are commonly made at 3–6 month reviews.
Realistic outcome measures
What outcomes should carers focus on rather than raw test scores?
Encourage carers to monitor practical abilities such as dressing, meal preparation, orientation and behaviour changes.
Quality‑of‑life markers and functional measures often provide the clearest signal of meaningful benefit.
| Evidence point | Practical implication |
|---|---|
| Modest cognitive benefit | Expect small improvements or slowed decline; review at 3–6 months |
| Tolerability limits continuation | Side‑effects may prompt discontinuation despite potential benefit |
| Variable response | Decisions should be individual and reviewed regularly |
- Carer counselling: Focus on everyday function, report side‑effects early, keep follow‑up appointments for review.
Key counselling points
- Starting dose and titration: the dose is increased step by step, usually every four weeks, and the medicine should be taken with food.
- Prolonged‑release capsules must be swallowed whole; do not crush or chew them.
- Gastrointestinal side effects are common and there is a small risk of bradycardia; report dizziness, fainting or a very slow heartbeat.
- Missed dose: take it when remembered unless the next dose is due soon; never double up.
- Suspected side effects can be reported via the Yellow Card scheme, and follow‑up appointments should be kept for dose review.
Frequently asked practical questions
Prescription status, storage and missed doses
Can galantamine be bought over the counter?
No, galantamine is a prescription‑only medicine in the UK.
How should it be stored?
Store at 20–25°C and protect from moisture and light.
Oral solution should be used within the manufacturer’s specified period after opening.
What if a dose is missed?
Take the missed dose when remembered unless the next dose is due soon; do not double up the dose.
Safety and travel queries
Is it safe to fly while taking galantamine?
Yes, but carry the original packaging and a copy of the prescription or patient information leaflet for customs and clarifying dosing across time zones.
What to do in overdose?
Seek urgent medical attention for signs of cholinergic crisis such as severe vomiting, muscle weakness or very slow heartbeat.
Can the drug be stopped abruptly?
Discuss with the prescriber; gradual discontinuation is generally preferable unless an urgent adverse reaction requires immediate cessation.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 9–21 days |
| Birmingham | West Midlands | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Manchester | Greater Manchester | 9–21 days |
| Leeds | West Yorkshire | 9–21 days |
| Liverpool | Merseyside | 9–21 days |
| Bristol | South West England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Sheffield | South Yorkshire | 9–21 days |
| Newcastle Upon Tyne | North East England | 9–21 days |
| Nottingham | Nottinghamshire | 9–21 days |
| Southampton | South East England | 9–21 days |
| Plymouth | South West England | 9–21 days |
